Reverse screening and target identification with minicells

• US 20030224369A1
• Filed: 05/28/2002
• Published: 12/04/2003
• Est. Priority Date: 02/25/2002
• Status: Abandoned Application

• Current Assignee: Mpex Biosciences, Inc.
• Original Assignee: Mpex Biosciences, Inc.
• Inventors: Berkley, Neil, Surber, Mark W., Gerhart, William
• Application Number:
  US10/157,171
• Publication Number:
  US 20030224369A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12N 15/00 Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor mutants or genetically engineered microorganisms, per se C12N1/00, C12N5/00, C12N7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H4/00; new animals per se A01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00
• CPC Class Codes: C12N 15/1037 Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
• CPC Class Codes: C12P 21/02 having a known sequence of two or more amino acids, e.g. glutathione
• CPC Class Codes: C40B 40/02 Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
• CPC Class Codes: G01N 33/5005 involving human or animal cells immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025
• CPC Class Codes: G01N 33/543 with an insoluble carrier for immobilising immunochemicals
• CPC Class Codes: G01N 33/5432 Liposomes or microcapsules
• CPC Class Codes: G01N 33/60 involving radioactive labelled substances

Abstract

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

Claims

1. A method of identifying a nucleic acid that encodes a protein that binds to or chemically alters a preselected ligand, comprising:

(a) separately contacting said ligand with individual members of a minicell library, wherein minicells in said library comprise expression elements, wherein said expression elements comprise DNA inserts, wherein an ORF in said DNA insert is operably linked to expression sequences, in order to generate a series of reaction mixes, each reaction mix comprising a different member of said minicell library;

(b) incubating said reaction mixes, thereby allowing a protein that binds to or chemically alters said preselected ligand to bind or chemically alter said preselected ligand;

(c) detecting a change in a signal from reaction mixes in which said ligand has been bound or chemically altered;

(d) preparing DNA from reaction mixes in which said ligand has been bound or chemically altered;

wherein said DNA is a nucleic acid that encodes a protein that binds to or chemically alters said preselected ligand.

2. The method of claim 1, wherein said minicell is a eubacterial minicell, a poroplast, a spheroplast or a protoplast.

3. The method of claim 1, wherein said preselected ligand is a biologically active compound.

4. The method of claim 1, wherein said preselected ligand is a therapeutic drug.

5. The method of claim 1, wherein a protein that binds or chemically alters said preselected ligand is a target protein for compounds that are therapeutic for a disease that is treated by administering said drug to an organism in need thereof.

6. The method of claim 1, wherein said preselected ligand is detectably labeled, said mincell comprises a detectable compound, and/or a chemically altered derivative of said protein is detectably labeled.

7. A method of determining the amino acid sequence of a protein that binds or chemically alters a preselected ligand, comprising:

(a) contacting said ligand with a minicell library, wherein minicells in said library comprise expression elements, wherein said expression elements comprise DNA inserts, wherein an ORF in said DNA insert is operably linked to expression sequences;

(b) incubating said mixture of ligand and minicells, under conditions which allow complexes comprising ligands and minicells to form and/or chemical reactions to occur;

(c) isolating or identifying said complexes from said ligand and said mixture of ligand and minicells;

(d) preparing DNA from an expression element found in one or more of said complexes, or in a minicell thereof;

(e) determining the nucleotide sequence of said ORF in said DNA;

(f) using the genetic code to predict an amino acid sequence encoded by said ORF, and

(g) wherein said amino acid sequence is or is derived from a protein that binds or chemically alters a preselected ligand.

8. The method of claim 7, wherein said minicell is a eubacterial minicell, a poroplast, a spheroplast or a protoplast.

9. The method of claim 7, wherein said DNA is prepared by isolating DNA from said complexes, or in a minicell thereof.

10. The method of claim 7, wherein said DNA is prepared by amplifying DNA from said complexes, or in a minicell thereof.

11. The method of claim 7, wherein said protein is a fusion protein.

12. The method of claim 7, wherein said protein is a membrane or a soluble protein.

13. The method of claim 12, wherein said protein comprises secretion sequences.

14. The method of claim 7, wherein said preselected ligand is a biologically active compound.

15. The method of claim 7, wherein said preselected ligand is a therapeutic drug.

16. The method of claim 7, wherein said preselected ligand is a therapeutic drug, and said protein that binds said preselected ligand is a target protein for compounds that are therapeutic for a disease that is treated by administering said drug to an organism in need thereof.

17. A method of identifying a nucleic acid that encodes a protein that inhibits or blocks an agent from binding to or chemically altering a preselected ligand, comprising:

(a) separately contacting said ligand with individual members of a minicell library, wherein minicells in said library comprise expression elements, wherein said expression elements comprise DNA inserts, wherein an ORF in said DNA insert is operably linked to expression sequences, in order to generate a series of reaction mixes, each reaction mix comprising a different member of said minicell library;

(b) incubating said reaction mixes, thereby allowing a protein that binds to or chemically alters said preselected ligand to bind or chemically alter said preselected ligand;

(c) detecting a change in a signal from reaction mixes in which said ligand has been bound or chemically altered;

(d) preparing DNA from reaction mixes in which said change in signal ligand has been bound or chemically altered;

wherein said DNA is a nucleic acid that encodes a protein that inhibits or blocks said agent from binding to or chemically altering said preselected ligand

18. The method of claim 17, wherein said minicell is a eubacterial minicell, a poroplast, a spheroplast or a protoplast.

19. The method of claim 17, wherein said DNA has a nucleotide sequence that encodes the amino acid sequence of said protein that inhibits or blocks said agent from binding to or chemically altering said preselected ligand.

20. The method of claim 17, wherein a protein that binds or chemically alters said preselected ligand is a target protein for compounds that are therapeutic for a disease that is treated by administering said drug to an organism in need thereof.